Diabetes Diagnosed At 75 Is A Different Illness

The same diagnosis at seventy-five and at forty-five describes different situations. The mechanism, the timeframe over which harm accumulates and the balance of treatment differ substantially.

The underlying physiology differs

Diabetes diagnosed in midlife typically involves marked insulin resistance associated with excess weight, with the pancreas compensating for years before failing.

Later-onset disease more often features reduced insulin secretion with less severe resistance, sometimes in people who are not overweight at all.

Age-related muscle loss contributes as well, since less muscle means less capacity to clear glucose after meals independently of body fat.

The timeframe for harm changes everything

The complications that tight glucose control prevents, particularly damage to small vessels in the eyes, kidneys and nerves, develop over one to two decades.

Someone diagnosed in their seventies may not have that interval available, so the expected benefit from very tight control is correspondingly smaller.

Cardiovascular risk operates on a shorter timescale, which is why blood pressure and lipid management often take priority over glucose targets in this group.

Low blood sugar becomes the greater danger

The main harm of intensive treatment is hypoglycaemia, and its consequences are considerably more serious in an older person.

A fall from hypoglycaemia can produce a fracture, and confusion or a cardiac event may follow, all of which arrive immediately rather than over decades.

Warning symptoms also become less reliable with age and with duration of disease, so episodes can progress further before being recognised.

Why targets are individualised

Most guidance now recommends looser glycated haemoglobin targets for older adults with limited life expectancy, several conditions or frailty.

The measurement itself is also less reliable in this group, because anaemia, kidney disease and altered red cell survival distort the result.

Individualisation means the target reflects that person's reserve, other conditions and priorities rather than a single number applied to everyone.

What this means in practice

It is worth knowing what target has been set and why, since many people are never told that theirs differs from a general figure.

Treatment intensity is periodically reviewed in both directions, and reducing medication where control has become tighter than intended is a recognised step.

Any episode of hypoglycaemia, and any unexplained fall or confusion in someone treated for diabetes, is a reason to seek review rather than to adjust anything independently.